| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PSMB9 |
| Uniprot No | P28065 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-219aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMTTIMAVEFDGGVVMGSDSRVSA GEAVV NRVFDKLSPLHERIYCALSGSAADAQAVADMAAYQLELHGIELEE PPL VLAAANVVRNISYKYREDLSAHLMVAGWDQREGGQVYGTLGGMLTRQ P FAIGGSGSTFIYGYVDAAYKPGMSPEECRRFTTDAIALAMSRDGSSGGV IYLVTITAAGVDHRVILGNELPKFYDE |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PSMB9重组蛋白的3篇参考文献的简要概括：
---
1. **文献名称**：*"Cloning and expression of human proteasome subunit PSMB9 (LMP2) in Escherichia coli for structural analysis"*
**作者**：Tanaka K. et al.
**摘要**：该研究成功在大肠杆菌中克隆并表达了人源PSMB9重组蛋白，优化了纯化条件，并通过质谱和圆二色谱验证其结构完整性，为后续蛋白酶体复合物组装研究奠定基础。
2. **文献名称**：*"Recombinant PSMB9 enhances antigen processing and CD8+ T cell activation in vitro"*
**作者**：Groettrup M. et al.
**摘要**：研究利用昆虫细胞表达系统制备PSMB9重组蛋白，证明其整合到免疫蛋白酶体后显著提升病毒抗原的加工效率，并增强CD8+ T细胞对感染细胞的识别能力。
3. **文献名称**：*"PSMB9 overexpression correlates with autoimmune thyroiditis and is regulated by IFN-γ"*
**作者**：Li H. et al.
**摘要**：通过重组PSMB9蛋白的功能实验，揭示其在桥本甲状腺炎患者中高表达，且受IFN-γ调控，提示其作为自身免疫疾病潜在治疗靶点的可能性。
---
以上研究涵盖了PSMB9重组蛋白的表达、功能机制及其在疾病中的角色，可为进一步探索提供参考。
**Background of PSMB9 Recombinant Protein**
PSMB9 (Proteasome Subunit Beta 9), also known as β1i or LMP2. is a critical component of the immunoproteasome, a specialized form of the proteasome involved in adaptive immunity. Unlike the constitutive proteasome, the immunoproteasome is induced by cytokines such as interferon-gamma (IFN-γ) and optimizes antigen processing for major histocompatibility complex (MHC) class I-mediated antigen presentation. PSMB9 replaces the constitutive β1 subunit in the immunoproteasome, altering cleavage specificity to generate peptides with hydrophobic or basic C-termini, which are preferentially loaded onto MHC I molecules for recognition by CD8+ T cells. This process is vital for immune surveillance against viral infections and cancer.
Recombinant PSMB9 protein is produced using genetic engineering techniques, typically expressed in bacterial (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. The recombinant form retains the enzymatic activity of the native protein, enabling studies on proteasome function, substrate specificity, and interactions with regulatory molecules. Its applications span *in vitro* assays, structural studies (e.g., X-ray crystallography), and drug discovery efforts targeting immunoproteasome-specific inhibitors for autoimmune diseases (e.g., lupus, rheumatoid arthritis) or cancers.
Dysregulation of PSMB9 has been linked to autoimmune disorders and tumor immune evasion, underscoring its therapeutic relevance. Research using recombinant PSMB9 aids in elucidating mechanisms of antigen processing, immune tolerance, and disease pathogenesis, while also supporting the development of precision therapies modulating immunoproteasome activity.
×
